Status:
COMPLETED
A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults
Lead Sponsor:
GlaxoSmithKline
Conditions:
Rhinitis, Allergic, Perennial
Eligibility:
All Genders
12-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the effect of an aqueous nasal spray investigational compound compared to placebo on the hypothalamic pituitary adrenocortical (HPA) axis system in adolescents a...
Detailed Description
A randomized, double-blind, parallel group, placebo and active (prednisone) controlled, 6-week study of the effect of GW685698X aqueous nasal spray 100mcg QD on the hypothalamic pituitary adrenocortic...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Diagnosis and history of perennial allergic rhinitis.
- Must be willing to stay overnight in the clinic at the beginning and end of the study for the collection of urine and blood samples over 24 hours.
- Must comply with all study procedures and be literate.
- Exclusion criteria:
- Use of tobacco products.
- Work a rotating shift.
- Significant concurrent medical conditions.
- Certain medications such as corticosteroids and allergy medications.
Exclusion
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00116818
Start Date
January 1 2005
End Date
May 1 2005
Last Update
September 15 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
San Antonio, Texas, United States, 78229
2
GSK Investigational Site
Mississauga, Ontario, Canada, L4W 1N2